Analysis explores how regulatory concepts impact aerosol drug development, suggesting improvements for efficiency.
By understanding the way the regulatory concepts of safety and effectiveness are interpreted by CDER, especially by the Division of Pulmonary Drug Products, value can be added to the data developed. Keeping regulatory requirements in mind during early product development aids rapid evaluation of aerosol drug candidates and can lead to more efficient decisions about further development. Health care practitioners, the medical research community, and patient advocates can and do have a voice in the development of new regulations.
No takes yet. Share an insight, caveat, or question.
Nancy Chew (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: